OncoMethylome Sciences "buy," target price raised

09/20/07 - ING Financial Markets

LONDON, September 20 (newratings.com) - Analyst Mark Clark of ING Financial Markets reiterates his "buy" rating on OncoMethylome Sciences SA (O6C). The 12-month target price has been raised from €13.3 to €16.2.

In a research note dated September 19 and published this morning, the analyst mentions that solid clinical data has raised confidence in the feasibility of the company’s colorectal and bladder cancer diagnostics. The clinical data underpins the wide applicability of DNA methylation detection in cancer diagnosis and monitoring, the analyst says. The upward revision in the target price reflects a higher probability of success of the bladder and the colorectal tests, ING Financial Markets adds.